Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RAayHgg0rwyy3VekvzOBUQRTWgFievCUPaLwH4aLWhYO4#assertion>. }
Showing items 1 to 13 of
13
with 100 items per page.
- DOID_1574 type Disease assertion.
- context type Cohort assertion.
- DRUGBANK:DB00334 type Drug assertion.
- association type Statement assertion.
- context label "adults" assertion.
- association label "Olanzapine was FDA approved for the treatment of schizophrenia and bipolar disorder only. It is an atypical antagonist of D2 and D4 receptors which determines a decrease in craving for alcohol. The DRD4 gene of dopamine presents a VNTR polymorphism, with a number of repetitions that varies from 2 to 11 which allows for the division of individuals in two subgroups: those with a number of repetitions between 2 and 6, classified as DRD4 S and those with more than 7 repetitions, classified as DRD4 L. Association studies between this variation and AUD have showed that individuals who carry the L allele exhibit greater craving after alcohol intake,50. Another study has investigated the association olanzapine-DRD4 showing that olanzapine reduces craving to the L allele carriers only, while no benefits were observed in S allele carriers." assertion.
- association subject DRUGBANK:DB00334 assertion.
- association predicate treats assertion.
- association object DOID_1574 assertion.
- association has_population_context context assertion.
- association relation OffLabelIndication assertion.
- association publications 29912214 assertion.
- association provided_by NeuroDKG assertion.